Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933733203> ?p ?o ?g. }
- W2933733203 endingPage "1146" @default.
- W2933733203 startingPage "1135" @default.
- W2933733203 abstract "Methotrexate-associated lymphoproliferative disorders are categorized as “other immunodeficiency-associated lymphoproliferative disorders in the WHO classification. Methotrexate-associated lymphoproliferative disorder is mainly a B-cell lymphoproliferative disorders or Hodgkin lymphoma type, whereas T-cell lymphoproliferative disorders are relatively rare (4–8%). Only a small number of methotrexate-associated T-cell lymphoproliferative disorders have been detailed thus far. Because of the rarity, methotrexate-associated T-cell lymphoproliferative disorder has not been well studied and its clinicopathological characteristics are unknown. A total of 28 cases of methotrexate-associated T-cell lymphoproliferative disorders were retrospectively analyzed. Histologically and immunohistochemically, they were divided into three main types: angioimmunoblastic T-cell lymphoma (n = 19), peripheral T-cell lymphoma, NOS (n = 6), and CD8+ cytotoxic T-cell lymphoma (n = 3). Among the 28 cases, only one CD8+ cytotoxic T-cell lymphoma case was Epstein-Barr virus-positive. The other 27 cases were negative for Epstein-Barr virus on tumor cells, but scattered Epstein-Barr virus-infected B-cells were detected in 24 cases (89%), implying the reactivation of Epstein-Barr virus caused by immunodeficient status of the patients. After the diagnosis of methotrexate-associated T-cell lymphoproliferative disorder, methotrexate was immediately withdrawn in 26 cases. Twenty (77%) cases presented with spontaneous regression. Compared to methotrexate-associated B-cell lymphoproliferative disorder, patients with methotrexate-associated T-cell lymphoproliferative disorder had a significantly higher proportion of males (p = 0.035) and presence of B-symptoms (p = 0.036), and lower proportion of Epstein-Barr virus+ tumor cells (p < 0.001). Although the difference was not significant, the methotrexate-associated T-cell lymphoproliferative disorder also had more frequent spontaneous regression (p = 0.061). In conclusion, methotrexate-associated T-cell lymphoproliferative disorder was divided into three main types: angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, NOS, and CD8+ cytotoxic T-cell lymphoma. Angioimmunoblastic T-cell lymphoma was the most common type. Methotrexate-associated T-cell lymphoproliferative disorder was characterized by a high rate of spontaneous regression after methotrexate cessation. Epstein-Barr virus positivity was relatively rare in methotrexate-associated T-cell lymphoproliferative disorder, significantly less frequent than methotrexate-associated B-cell lymphoproliferative disorder, suggesting different pathogenesis." @default.
- W2933733203 created "2019-04-11" @default.
- W2933733203 creator A5001399725 @default.
- W2933733203 creator A5022669828 @default.
- W2933733203 creator A5029594974 @default.
- W2933733203 creator A5034433475 @default.
- W2933733203 creator A5053906265 @default.
- W2933733203 creator A5056557726 @default.
- W2933733203 creator A5056944762 @default.
- W2933733203 creator A5059183289 @default.
- W2933733203 creator A5063147479 @default.
- W2933733203 creator A5068557516 @default.
- W2933733203 creator A5074447395 @default.
- W2933733203 creator A5075759339 @default.
- W2933733203 creator A5079163477 @default.
- W2933733203 creator A5086823047 @default.
- W2933733203 date "2019-08-01" @default.
- W2933733203 modified "2023-10-16" @default.
- W2933733203 title "Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases" @default.
- W2933733203 cites W1814283377 @default.
- W2933733203 cites W1968394087 @default.
- W2933733203 cites W1980827798 @default.
- W2933733203 cites W1981296618 @default.
- W2933733203 cites W1989574614 @default.
- W2933733203 cites W1994668260 @default.
- W2933733203 cites W1996715439 @default.
- W2933733203 cites W2017497764 @default.
- W2933733203 cites W2020094108 @default.
- W2933733203 cites W2021537093 @default.
- W2933733203 cites W2036510118 @default.
- W2933733203 cites W2047505662 @default.
- W2933733203 cites W2048266154 @default.
- W2933733203 cites W2050182784 @default.
- W2933733203 cites W2061220719 @default.
- W2933733203 cites W2067174344 @default.
- W2933733203 cites W2068649220 @default.
- W2933733203 cites W2076226859 @default.
- W2933733203 cites W2080382012 @default.
- W2933733203 cites W2131745105 @default.
- W2933733203 cites W2136673620 @default.
- W2933733203 cites W2145446076 @default.
- W2933733203 cites W2511711730 @default.
- W2933733203 cites W2604476006 @default.
- W2933733203 cites W2790303104 @default.
- W2933733203 cites W2794363653 @default.
- W2933733203 cites W4234797131 @default.
- W2933733203 doi "https://doi.org/10.1038/s41379-019-0264-2" @default.
- W2933733203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30952973" @default.
- W2933733203 hasPublicationYear "2019" @default.
- W2933733203 type Work @default.
- W2933733203 sameAs 2933733203 @default.
- W2933733203 citedByCount "17" @default.
- W2933733203 countsByYear W29337332032019 @default.
- W2933733203 countsByYear W29337332032020 @default.
- W2933733203 countsByYear W29337332032021 @default.
- W2933733203 countsByYear W29337332032022 @default.
- W2933733203 countsByYear W29337332032023 @default.
- W2933733203 crossrefType "journal-article" @default.
- W2933733203 hasAuthorship W2933733203A5001399725 @default.
- W2933733203 hasAuthorship W2933733203A5022669828 @default.
- W2933733203 hasAuthorship W2933733203A5029594974 @default.
- W2933733203 hasAuthorship W2933733203A5034433475 @default.
- W2933733203 hasAuthorship W2933733203A5053906265 @default.
- W2933733203 hasAuthorship W2933733203A5056557726 @default.
- W2933733203 hasAuthorship W2933733203A5056944762 @default.
- W2933733203 hasAuthorship W2933733203A5059183289 @default.
- W2933733203 hasAuthorship W2933733203A5063147479 @default.
- W2933733203 hasAuthorship W2933733203A5068557516 @default.
- W2933733203 hasAuthorship W2933733203A5074447395 @default.
- W2933733203 hasAuthorship W2933733203A5075759339 @default.
- W2933733203 hasAuthorship W2933733203A5079163477 @default.
- W2933733203 hasAuthorship W2933733203A5086823047 @default.
- W2933733203 hasBestOaLocation W29337332031 @default.
- W2933733203 hasConcept C142724271 @default.
- W2933733203 hasConcept C147483822 @default.
- W2933733203 hasConcept C167672396 @default.
- W2933733203 hasConcept C203014093 @default.
- W2933733203 hasConcept C2522874641 @default.
- W2933733203 hasConcept C2776995267 @default.
- W2933733203 hasConcept C2779338263 @default.
- W2933733203 hasConcept C2781059491 @default.
- W2933733203 hasConcept C2781375147 @default.
- W2933733203 hasConcept C71924100 @default.
- W2933733203 hasConceptScore W2933733203C142724271 @default.
- W2933733203 hasConceptScore W2933733203C147483822 @default.
- W2933733203 hasConceptScore W2933733203C167672396 @default.
- W2933733203 hasConceptScore W2933733203C203014093 @default.
- W2933733203 hasConceptScore W2933733203C2522874641 @default.
- W2933733203 hasConceptScore W2933733203C2776995267 @default.
- W2933733203 hasConceptScore W2933733203C2779338263 @default.
- W2933733203 hasConceptScore W2933733203C2781059491 @default.
- W2933733203 hasConceptScore W2933733203C2781375147 @default.
- W2933733203 hasConceptScore W2933733203C71924100 @default.
- W2933733203 hasIssue "8" @default.
- W2933733203 hasLocation W29337332031 @default.
- W2933733203 hasLocation W29337332032 @default.
- W2933733203 hasOpenAccess W2933733203 @default.
- W2933733203 hasPrimaryLocation W29337332031 @default.